Osteoporosis is one of the key healthcare problems across the world. According to the international experts, this condition has become a virtual epidemic. The principal feature distinguishing osteoporosis from the other locomotor apparatus diseases is an almost entire absence of clinical manifestations up to the fracture occurring. Only one in three vertebral fractures is clinically detected (Briggs A.M., 2007; Genant H.K., 2002; Поворознюк В.В., 2009).

Taking into account a significant medico-social importance of osteoporosis, it is very important to evaluate the bone tissue at the early stages.

«Dual X- Ray absorptiometry is considered a ‘gold standard’ of bone mineral assessment.

1. Women of 65 years and over.
2. Postmenopausal women younger than 65 years with the following risk factors: low body mass, previous fractures, medications affecting the bone tissue, conditions associated with bone loss.
3. Perimenopausal women with clinical risk factors: low body mass, previous fractures, medications affecting the bone tissue.
4. Men of 70 years and over.
5. Men younger than 70 years with the following risk factors: low body mass, previous fractures, medications affecting the bone tissue, conditions associated with bone loss.
6. Patients with previous fragility fractures.
7. Patients with conditions associated with bone loss.
8. Patients on medications affecting the bone tissue.

Go to the center

2019 EUROPEAN RECOMMENDATIONS ON SARCOPENIA DIAGNOSTICS (EWGSOP, 2019)

Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019 Jan 1;48(1):16-31. doi: 10.1093/ageing/afy169.

According to the revised European Working Group on Sarcopenia in Older People (EWGSOP) consensus of 2019, sarcopenia is a progressive and generalised skeletal muscle disorder that is associated with increased likelihood of adverse outcomes including falls, fractures, physical disability and mortality.

In September 2016, the diagnosis of sarcopenia was officially included in the supplemented 10th international classification of diseases under the code M 62.84

Diagnostic criteria (EWGSOP, 2019):

1. Low muscle strength
2. Low muscle quantity or quality
3. Low physical performance

Sarcopenia stages (EWGSOP, 2019)

Sarcopenia “cut-off” points (EWGSOP, 2019)

2019 EWGSOP’s updated diagnostic («Find-Asess-Confirm-Severity» (F-A-C-S)) algorithm targeted at sarcopenia

SARC-F: sarcopenia diagnostic questionnaire

Interpretation of findings: total value of over 4 points indicates a high probability of sarcopenia and its adverse consequences in an examined patient.

N.I. Dzerovych

2019 European recommendations on sarcopenia diagnosis

http://osteoporos.com.ua/uk/ukrainska-asociacija-osteoporozu/publikatsii/zhurnal2 

In June 4, 2016 Prof. Vladyslav Volodymyrovych Povoroznyuk, President of the Ukrainian Association of Osteoporosis was awarded at the annual summit of the International Society for Clinical Densitometry (ISCD) held in Galway, Ireland, for his leadership and significant achievements in clinical densitometry with John P. Bilezikian ISCD Global Leadership Award. (John P. Bilezikian ISCD Global Leadership Award).

In April 2-5, 2014 in Seville, Spain, the World Congress of Osteoporosis, Osteoarthritis, and Bone and Joint Diseases was held under the auspices of the (International osteoporosis Foundation (IOF)) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO).

In 2014, the IOF’s Committee established a Medal for the active participation in the Committee of National Societies (CNS)’s activities and spreading the IOF’s mission.

Prof. Vladyslav Volodymyrovych Povoroznyuk, President of the Ukrainian Association of Osteoporosis, was chosen as the first awardee.

J. Stenmark, Managing Director of the International osteoporosis Foundation (IOF); Prof. Vladyslav Volodymyrovych Povoroznyuk, President of the Ukrainian Association of Osteoporosis; J. Reginster, President of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO).